APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti Obesity Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Anti Obesity Drugs Market Analysis and Forecast 2026-2032

29 December 2025199 pages

Choose your research edition.

Industry ResearchAnti Obesity Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti Obesity Drugs Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Anti Obesity Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti Obesity Drugs Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti Obesity Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Anti Obesity Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Anti Obesity Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Anti Obesity Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Anti Obesity Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Anti Obesity Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Anti Obesity Drugs include Wanhan Pharma, ZENIN Biotechnology, Teva, Novartis, Roche, Lunan Pharma, Eli Lilly, VIVUS and Pharscin Pharma, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Anti Obesity Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Anti Obesity Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Anti Obesity Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Anti Obesity Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Anti Obesity Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Anti Obesity Drugs revenue, projected growth trends, production technology, application and end-user industry.

Anti Obesity Drugs Segment by Company

Wanhan Pharma

ZENIN Biotechnology

Teva

Novartis

Roche

Lunan Pharma

Eli Lilly

VIVUS

Pharscin Pharma

Novo Nordisk

Lupin Laboratories

iNova Pharmaceuticals

Hypera Pharma

GlaxoSmithKline

Alvogen

Anti Obesity Drugs Segment by Type

Injection

Oral

Anti Obesity Drugs Segment by Application

Hospital

Retail Pharmacy

Other

Anti Obesity Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti Obesity Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti Obesity Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti Obesity Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Anti Obesity Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Anti Obesity Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Anti Obesity Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Anti Obesity Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Injection Major Player Table 3. Oral Major Player Table 4. Global Anti Obesity Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Retail Pharmacy Major Player Table 7. Other Major Player Table 8. Anti Obesity Drugs Industry Trends Table 9. Anti Obesity Drugs Industry Drivers Table 10. Anti Obesity Drugs Industry Opportunities and Challenges Table 11. Anti Obesity Drugs Industry Restraints Table 12. Global Anti Obesity Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Anti Obesity Drugs Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Anti Obesity Drugs Market Share by Region (2021-2026) Table 15. Global Anti Obesity Drugs Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Anti Obesity Drugs Market Share by Region (2027-2032) Table 17. Global Anti Obesity Drugs Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Anti Obesity Drugs Revenue Market Share by Players (2021-2026) Table 19. Global Anti Obesity Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Anti Obesity Drugs Key Players Headquarters & Area Served Table 21. Global Anti Obesity Drugs Players, Product Type & Application Table 22. Global Anti Obesity Drugs Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Anti Obesity Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Anti Obesity Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Anti Obesity Drugs Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Anti Obesity Drugs Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Anti Obesity Drugs Revenue Market Share by Type (2021-2026) Table 29. Global Anti Obesity Drugs Revenue Market Share by Type (2027-2032) Table 30. Global Anti Obesity Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Anti Obesity Drugs Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Anti Obesity Drugs Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Anti Obesity Drugs Revenue Market Share by Application (2021-2026) Table 34. Global Anti Obesity Drugs Revenue Market Share by Application (2027-2032) Table 35. Wanhan Pharma Company Information Table 36. Wanhan Pharma Business Overview Table 37. Wanhan Pharma Anti Obesity Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Wanhan Pharma Anti Obesity Drugs Product Portfolio Table 39. Wanhan Pharma Recent Development Table 40. ZENIN Biotechnology Company Information Table 41. ZENIN Biotechnology Business Overview Table 42. ZENIN Biotechnology Anti Obesity Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. ZENIN Biotechnology Anti Obesity Drugs Product Portfolio Table 44. ZENIN Biotechnology Recent Development Table 45. Teva Company Information Table 46. Teva Business Overview Table 47. Teva Anti Obesity Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Teva Anti Obesity Drugs Product Portfolio Table 49. Teva Recent Development Table 50. Novartis Company Information Table 51. Novartis Business Overview Table 52. Novartis Anti Obesity Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Novartis Anti Obesity Drugs Product Portfolio Table 54. Novartis Recent Development Table 55. Roche Company Information Table 56. Roche Business Overview Table 57. Roche Anti Obesity Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Roche Anti Obesity Drugs Product Portfolio Table 59. Roche Recent Development Table 60. Lunan Pharma Company Information Table 61. Lunan Pharma Business Overview Table 62. Lunan Pharma Anti Obesity Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Lunan Pharma Anti Obesity Drugs Product Portfolio Table 64. Lunan Pharma Recent Development Table 65. Eli Lilly Company Information Table 66. Eli Lilly Business Overview Table 67. Eli Lilly Anti Obesity Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Eli Lilly Anti Obesity Drugs Product Portfolio Table 69. Eli Lilly Recent Development Table 70. VIVUS Company Information Table 71. VIVUS Business Overview Table 72. VIVUS Anti Obesity Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. VIVUS Anti Obesity Drugs Product Portfolio Table 74. VIVUS Recent Development Table 75. Pharscin Pharma Company Information Table 76. Pharscin Pharma Business Overview Table 77. Pharscin Pharma Anti Obesity Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Pharscin Pharma Anti Obesity Drugs Product Portfolio Table 79. Pharscin Pharma Recent Development Table 80. Novo Nordisk Company Information Table 81. Novo Nordisk Business Overview Table 82. Novo Nordisk Anti Obesity Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Novo Nordisk Anti Obesity Drugs Product Portfolio Table 84. Novo Nordisk Recent Development Table 85. Lupin Laboratories Company Information Table 86. Lupin Laboratories Business Overview Table 87. Lupin Laboratories Anti Obesity Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Lupin Laboratories Anti Obesity Drugs Product Portfolio Table 89. Lupin Laboratories Recent Development Table 90. iNova Pharmaceuticals Company Information Table 91. iNova Pharmaceuticals Business Overview Table 92. iNova Pharmaceuticals Anti Obesity Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. iNova Pharmaceuticals Anti Obesity Drugs Product Portfolio Table 94. iNova Pharmaceuticals Recent Development Table 95. Hypera Pharma Company Information Table 96. Hypera Pharma Business Overview Table 97. Hypera Pharma Anti Obesity Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Hypera Pharma Anti Obesity Drugs Product Portfolio Table 99. Hypera Pharma Recent Development Table 100. GlaxoSmithKline Company Information Table 101. GlaxoSmithKline Business Overview Table 102. GlaxoSmithKline Anti Obesity Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. GlaxoSmithKline Anti Obesity Drugs Product Portfolio Table 104. GlaxoSmithKline Recent Development Table 105. Alvogen Company Information Table 106. Alvogen Business Overview Table 107. Alvogen Anti Obesity Drugs Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Alvogen Anti Obesity Drugs Product Portfolio Table 109. Alvogen Recent Development Table 110. North America Anti Obesity Drugs Revenue by Type (2021-2026) & (US$ Million) Table 111. North America Anti Obesity Drugs Revenue by Type (2027-2032) & (US$ Million) Table 112. North America Anti Obesity Drugs Revenue by Application (2021-2026) & (US$ Million) Table 113. North America Anti Obesity Drugs Revenue by Application (2027-2032) & (US$ Million) Table 114. North America Anti Obesity Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. North America Anti Obesity Drugs Revenue by Country (2021-2026) & (US$ Million) Table 116. North America Anti Obesity Drugs Revenue by Country (US$ Million) & (2027-2032) Table 117. Europe Anti Obesity Drugs Revenue by Type (2021-2026) & (US$ Million) Table 118. Europe Anti Obesity Drugs Revenue by Type (2027-2032) & (US$ Million) Table 119. Europe Anti Obesity Drugs Revenue by Application (2021-2026) & (US$ Million) Table 120. Europe Anti Obesity Drugs Revenue by Application (2027-2032) & (US$ Million) Table 121. Europe Anti Obesity Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. Europe Anti Obesity Drugs Revenue by Country (2021-2026) & (US$ Million) Table 123. Europe Anti Obesity Drugs Revenue by Country (US$ Million) & (2027-2032) Table 124. China Anti Obesity Drugs Revenue by Type (2021-2026) & (US$ Million) Table 125. China Anti Obesity Drugs Revenue by Type (2027-2032) & (US$ Million) Table 126. China Anti Obesity Drugs Revenue by Application (2021-2026) & (US$ Million) Table 127. China Anti Obesity Drugs Revenue by Application (2027-2032) & (US$ Million) Table 128. Asia Anti Obesity Drugs Revenue by Type (2021-2026) & (US$ Million) Table 129. Asia Anti Obesity Drugs Revenue by Type (2027-2032) & (US$ Million) Table 130. Asia Anti Obesity Drugs Revenue by Application (2021-2026) & (US$ Million) Table 131. Asia Anti Obesity Drugs Revenue by Application (2027-2032) & (US$ Million) Table 132. Asia Anti Obesity Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 133. Asia Anti Obesity Drugs Revenue by Region (US$ Million) & (2021-2026) Table 134. Asia Anti Obesity Drugs Revenue by Region (US$ Million) & (2027-2032) Table 135. SAMEA Anti Obesity Drugs Revenue by Type (2021-2026) & (US$ Million) Table 136. SAMEA Anti Obesity Drugs Revenue by Type (2027-2032) & (US$ Million) Table 137. SAMEA Anti Obesity Drugs Revenue by Application (2021-2026) & (US$ Million) Table 138. SAMEA Anti Obesity Drugs Revenue by Application (2027-2032) & (US$ Million) Table 139. SAMEA Anti Obesity Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 140. SAMEA Anti Obesity Drugs Revenue by Country (2021-2026) & (US$ Million) Table 141. SAMEA Anti Obesity Drugs Revenue by Country (US$ Million) & (2027-2032) Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Anti Obesity Drugs Image Figure 2. Global Anti Obesity Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti Obesity Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Injection Image Figure 5. Oral Image Figure 6. Global Anti Obesity Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Anti Obesity Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Retail Pharmacy Image Figure 10. Other Image Figure 11. Global Anti Obesity Drugs Market Size (US$ Million) & (2021-2032) Figure 12. Global Anti Obesity Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Anti Obesity Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Anti Obesity Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Anti Obesity Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Anti Obesity Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Anti Obesity Drugs Revenue Market Share by Type (2021-2032) Figure 19. Global Anti Obesity Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Anti Obesity Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Anti Obesity Drugs Revenue Market Share by Application (2021-2032) Figure 22. North America Anti Obesity Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Anti Obesity Drugs Revenue Share by Type (2021-2032) Figure 24. North America Anti Obesity Drugs Revenue Share by Application (2021-2032) Figure 25. North America Anti Obesity Drugs Revenue Share by Country (2021-2032) Figure 26. United States Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Anti Obesity Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Anti Obesity Drugs Revenue Share by Type (2021-2032) Figure 31. Europe Anti Obesity Drugs Revenue Share by Application (2021-2032) Figure 32. Europe Anti Obesity Drugs Revenue Share by Country (2021-2032) Figure 33. Germany Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Anti Obesity Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Anti Obesity Drugs Revenue Share by Type (2021-2032) Figure 43. China Anti Obesity Drugs Revenue Share by Application (2021-2032) Figure 44. Asia Anti Obesity Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Anti Obesity Drugs Revenue Share by Type (2021-2032) Figure 46. Asia Anti Obesity Drugs Revenue Share by Application (2021-2032) Figure 47. Asia Anti Obesity Drugs Revenue Share by Region (2021-2032) Figure 48. Japan Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Anti Obesity Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Anti Obesity Drugs Revenue Share by Type (2021-2032) Figure 56. SAMEA Anti Obesity Drugs Revenue Share by Application (2021-2032) Figure 57. SAMEA Anti Obesity Drugs Revenue Share by Country (2021-2032) Figure 58. Brazil Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Anti Obesity Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • Oral
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Wanhan Pharma
  • ZENIN Biotechnology
  • Teva
  • Novartis
  • Roche
  • Lunan Pharma
  • Eli Lilly
  • VIVUS
  • Pharscin Pharma
  • Novo Nordisk
  • Lupin Laboratories
  • iNova Pharmaceuticals
  • Hypera Pharma
  • GlaxoSmithKline
  • Alvogen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Anti Obesity Drugs Market by Type
  3. 1.2.1 Global Anti Obesity Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Injection
  5. 1.2.3 Oral
  6. 1.3 Anti Obesity Drugs Market by Application
  7. 1.3.1 Global Anti Obesity Drugs Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Retail Pharmacy
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Anti Obesity Drugs Market Dynamics
  1. 2.1 Anti Obesity Drugs Industry Trends
  2. 2.2 Anti Obesity Drugs Industry Drivers
  3. 2.3 Anti Obesity Drugs Industry Opportunities and Challenges
  4. 2.4 Anti Obesity Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Anti Obesity Drugs Market Perspective (2021-2032)
  2. 3.2 Global Anti Obesity Drugs Growth Trends by Region
  3. 3.2.1 Global Anti Obesity Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Anti Obesity Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Anti Obesity Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Anti Obesity Drugs Revenue by Players
  2. 4.1.1 Global Anti Obesity Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Anti Obesity Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Anti Obesity Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Anti Obesity Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Anti Obesity Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Anti Obesity Drugs Players, Product Type & Application
  8. 4.5 Global Anti Obesity Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Anti Obesity Drugs Market CR5 and HHI
  11. 4.6.3 2025 Anti Obesity Drugs Tier 1, Tier 2, and Tier 3
5 Anti Obesity Drugs Market Size by Type
  1. 5.1 Global Anti Obesity Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Anti Obesity Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Anti Obesity Drugs Revenue Market Share by Type (2021-2032)
6 Anti Obesity Drugs Market Size by Application
  1. 6.1 Global Anti Obesity Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Anti Obesity Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Anti Obesity Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Wanhan Pharma
  2. 7.1.1 Wanhan Pharma Company Information
  3. 7.1.2 Wanhan Pharma Business Overview
  4. 7.1.3 Wanhan Pharma Anti Obesity Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Wanhan Pharma Anti Obesity Drugs Product Portfolio
  6. 7.1.5 Wanhan Pharma Recent Developments
  7. 7.2 ZENIN Biotechnology
  8. 7.2.1 ZENIN Biotechnology Company Information
  9. 7.2.2 ZENIN Biotechnology Business Overview
  10. 7.2.3 ZENIN Biotechnology Anti Obesity Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 ZENIN Biotechnology Anti Obesity Drugs Product Portfolio
  12. 7.2.5 ZENIN Biotechnology Recent Developments
  13. 7.3 Teva
  14. 7.3.1 Teva Company Information
  15. 7.3.2 Teva Business Overview
  16. 7.3.3 Teva Anti Obesity Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Teva Anti Obesity Drugs Product Portfolio
  18. 7.3.5 Teva Recent Developments
  19. 7.4 Novartis
  20. 7.4.1 Novartis Company Information
  21. 7.4.2 Novartis Business Overview
  22. 7.4.3 Novartis Anti Obesity Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Novartis Anti Obesity Drugs Product Portfolio
  24. 7.4.5 Novartis Recent Developments
  25. 7.5 Roche
  26. 7.5.1 Roche Company Information
  27. 7.5.2 Roche Business Overview
  28. 7.5.3 Roche Anti Obesity Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Roche Anti Obesity Drugs Product Portfolio
  30. 7.5.5 Roche Recent Developments
  31. 7.6 Lunan Pharma
  32. 7.6.1 Lunan Pharma Company Information
  33. 7.6.2 Lunan Pharma Business Overview
  34. 7.6.3 Lunan Pharma Anti Obesity Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Lunan Pharma Anti Obesity Drugs Product Portfolio
  36. 7.6.5 Lunan Pharma Recent Developments
  37. 7.7 Eli Lilly
  38. 7.7.1 Eli Lilly Company Information
  39. 7.7.2 Eli Lilly Business Overview
  40. 7.7.3 Eli Lilly Anti Obesity Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Eli Lilly Anti Obesity Drugs Product Portfolio
  42. 7.7.5 Eli Lilly Recent Developments
  43. 7.8 VIVUS
  44. 7.8.1 VIVUS Company Information
  45. 7.8.2 VIVUS Business Overview
  46. 7.8.3 VIVUS Anti Obesity Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 VIVUS Anti Obesity Drugs Product Portfolio
  48. 7.8.5 VIVUS Recent Developments
  49. 7.9 Pharscin Pharma
  50. 7.9.1 Pharscin Pharma Company Information
  51. 7.9.2 Pharscin Pharma Business Overview
  52. 7.9.3 Pharscin Pharma Anti Obesity Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Pharscin Pharma Anti Obesity Drugs Product Portfolio
  54. 7.9.5 Pharscin Pharma Recent Developments
  55. 7.10 Novo Nordisk
  56. 7.10.1 Novo Nordisk Company Information
  57. 7.10.2 Novo Nordisk Business Overview
  58. 7.10.3 Novo Nordisk Anti Obesity Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Novo Nordisk Anti Obesity Drugs Product Portfolio
  60. 7.10.5 Novo Nordisk Recent Developments
  61. 7.11 Lupin Laboratories
  62. 7.11.1 Lupin Laboratories Company Information
  63. 7.11.2 Lupin Laboratories Business Overview
  64. 7.11.3 Lupin Laboratories Anti Obesity Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Lupin Laboratories Anti Obesity Drugs Product Portfolio
  66. 7.11.5 Lupin Laboratories Recent Developments
  67. 7.12 iNova Pharmaceuticals
  68. 7.12.1 iNova Pharmaceuticals Company Information
  69. 7.12.2 iNova Pharmaceuticals Business Overview
  70. 7.12.3 iNova Pharmaceuticals Anti Obesity Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 iNova Pharmaceuticals Anti Obesity Drugs Product Portfolio
  72. 7.12.5 iNova Pharmaceuticals Recent Developments
  73. 7.13 Hypera Pharma
  74. 7.13.1 Hypera Pharma Company Information
  75. 7.13.2 Hypera Pharma Business Overview
  76. 7.13.3 Hypera Pharma Anti Obesity Drugs Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Hypera Pharma Anti Obesity Drugs Product Portfolio
  78. 7.13.5 Hypera Pharma Recent Developments
  79. 7.14 GlaxoSmithKline
  80. 7.14.1 GlaxoSmithKline Company Information
  81. 7.14.2 GlaxoSmithKline Business Overview
  82. 7.14.3 GlaxoSmithKline Anti Obesity Drugs Revenue and Gross Margin (2021-2026)
  83. 7.14.4 GlaxoSmithKline Anti Obesity Drugs Product Portfolio
  84. 7.14.5 GlaxoSmithKline Recent Developments
  85. 7.15 Alvogen
  86. 7.15.1 Alvogen Company Information
  87. 7.15.2 Alvogen Business Overview
  88. 7.15.3 Alvogen Anti Obesity Drugs Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Alvogen Anti Obesity Drugs Product Portfolio
  90. 7.15.5 Alvogen Recent Developments
8 North America
  1. 8.1 North America Anti Obesity Drugs Revenue (2021-2032)
  2. 8.2 North America Anti Obesity Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Anti Obesity Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Anti Obesity Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Anti Obesity Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Anti Obesity Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Anti Obesity Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Anti Obesity Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Anti Obesity Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Anti Obesity Drugs Revenue by Country
  11. 8.6.1 North America Anti Obesity Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Anti Obesity Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Anti Obesity Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Anti Obesity Drugs Revenue (2021-2032)
  2. 9.2 Europe Anti Obesity Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Anti Obesity Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Anti Obesity Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Anti Obesity Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Anti Obesity Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Anti Obesity Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Anti Obesity Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Anti Obesity Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Anti Obesity Drugs Revenue by Country
  11. 9.6.1 Europe Anti Obesity Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Anti Obesity Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Anti Obesity Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Anti Obesity Drugs Revenue (2021-2032)
  2. 10.2 China Anti Obesity Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Anti Obesity Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Anti Obesity Drugs Revenue by Type (2027-2032)
  5. 10.3 China Anti Obesity Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Anti Obesity Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Anti Obesity Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Anti Obesity Drugs Revenue by Application (2027-2032)
  9. 10.5 China Anti Obesity Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Anti Obesity Drugs Revenue (2021-2032)
  2. 11.2 Asia Anti Obesity Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Anti Obesity Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Anti Obesity Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Anti Obesity Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Anti Obesity Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Anti Obesity Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Anti Obesity Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Anti Obesity Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Anti Obesity Drugs Revenue by Country
  11. 11.6.1 Asia Anti Obesity Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Anti Obesity Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Anti Obesity Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Anti Obesity Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Anti Obesity Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Anti Obesity Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Anti Obesity Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Anti Obesity Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Anti Obesity Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Anti Obesity Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Anti Obesity Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Anti Obesity Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Anti Obesity Drugs Revenue by Country
  11. 12.6.1 SAMEA Anti Obesity Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Anti Obesity Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Anti Obesity Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst